Biond Biologics hopes its therapy, which activates 3 separate immune pathways, will prove to be 'strong and sustained anti-tumor response,' says CEO; human trials to start mid-2021

Under the terms of license agreement, Biond could get $1 billion as milestones met; Sanofi will be in charge of commercialization and clinical development